Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility

Table 4

Summary of induction and maintenance treatment: breakdown of patients with ESRD or death, CKD, and preservation of renal function.

Therapy	Induction: ESRD/death, % (n = 15)	Maintenance: ESRD/death, % (n = 15)	Induction: CKD, % (n = 15)	Maintenance: CKD, % (n = 15)	Induction: preservation of renal function, % (n = 6)	Maintenance: preservation of renal function, % (n = 6)
Cyclophosphamide	66.7 (10)	0 (0)	73.3 (11)	0 (0)	50 (3)	0 (0)
Rituximab	13.3 (2)	6.7 (1)	13.3 (2)	13.3 (2)	50 (3)	50 (3)
Cyclophosphamide and rituximab	0(0)	0 (0)	6.7 (1)	0 (0)	0 (0)	0 (0)
Azathioprine	20 (3)	60 (9)	6.7 (1)	73.3 (11)	0 (0)	33.3 (2)
Corticosteroids alone	0 (0)	26.7 (4)	0 (0)	13.3 (2)	0 (0)	0 (0)
Other (MMF)	0 (0)	6.7 (1)	0 (0)	0 (0)	0 (0)	0 (0)
No treatment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	16.7 (1)